Attributes | Values |
---|
rdf:type
| |
Description
| - Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males worldwide. Due to its high incidence and mortality, early diagnosis, identification of highly aggressive forms of clinically silent and understanding of disease pathogenesis with typical metabolic differences in order to develop specifically targeted therapy are needed [1]. As a results of numerous studies on cell as well as on prostate cancer patients, there have been found several compounds connected with tumourigenesis in prostate cells including Bcl-2. This intracellular protein belongs to a large group of proteins called %22Bcl-2 family%22. Bcl-2 acts as an inhibitor of apoptosis. It has been suggested that overexpression of the Bcl-2 oncoprotein in human cancer cells contributes to their resistance to chemotherapy- and radiotherapy-induced apoptosis and is connected with unfavourable prognosis. In the fact, the majority of human prostate tumours overexpress Bcl-2, which is responsible for tumours resistance to radiotherapy and chemotherapy. Moreover, it has been reported that Bcl-2 expression is associated with tumour progression and unfavourable prognosis in prostate cancer patients and is associated with the development of androgen-independent prostate cancer. Possible associations with other proteins connected with tumour processes as c-Fos, c-Jun, Ki-67, NF-kB and p53 can be assumed. Therefore, we aimed our attention on determining of expression of Bcl-2, c-Fos, c-Jun, Ki-67, NF-kB and p53 genes in two prostate cell lines as 22Rv1 cell line, a model of aggressive partially androgen-sensitive prostate cancer and as PNT1A cell line, a model of healthy cell line. Moreover, we were interested in the issue how exposure of these cell lines to zinc(II) ions could influence expression of the above mentioned genes. We found that zinc(II) ions caused elevated expression of Ki-67, a marker of proliferation, extremely low expression of p53, high expression
- Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males worldwide. Due to its high incidence and mortality, early diagnosis, identification of highly aggressive forms of clinically silent and understanding of disease pathogenesis with typical metabolic differences in order to develop specifically targeted therapy are needed [1]. As a results of numerous studies on cell as well as on prostate cancer patients, there have been found several compounds connected with tumourigenesis in prostate cells including Bcl-2. This intracellular protein belongs to a large group of proteins called %22Bcl-2 family%22. Bcl-2 acts as an inhibitor of apoptosis. It has been suggested that overexpression of the Bcl-2 oncoprotein in human cancer cells contributes to their resistance to chemotherapy- and radiotherapy-induced apoptosis and is connected with unfavourable prognosis. In the fact, the majority of human prostate tumours overexpress Bcl-2, which is responsible for tumours resistance to radiotherapy and chemotherapy. Moreover, it has been reported that Bcl-2 expression is associated with tumour progression and unfavourable prognosis in prostate cancer patients and is associated with the development of androgen-independent prostate cancer. Possible associations with other proteins connected with tumour processes as c-Fos, c-Jun, Ki-67, NF-kB and p53 can be assumed. Therefore, we aimed our attention on determining of expression of Bcl-2, c-Fos, c-Jun, Ki-67, NF-kB and p53 genes in two prostate cell lines as 22Rv1 cell line, a model of aggressive partially androgen-sensitive prostate cancer and as PNT1A cell line, a model of healthy cell line. Moreover, we were interested in the issue how exposure of these cell lines to zinc(II) ions could influence expression of the above mentioned genes. We found that zinc(II) ions caused elevated expression of Ki-67, a marker of proliferation, extremely low expression of p53, high expression (en)
|
Title
| - Expression of Bcl-2 and other regulatory genes in tumour prostate cell lines
- Expression of Bcl-2 and other regulatory genes in tumour prostate cell lines (en)
|
skos:prefLabel
| - Expression of Bcl-2 and other regulatory genes in tumour prostate cell lines
- Expression of Bcl-2 and other regulatory genes in tumour prostate cell lines (en)
|
skos:notation
| - RIV/62156489:43210/12:00198480!RIV13-GA0-43210___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/62156489:43210/12:00198480
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - marker; expresion; cell (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - International Journal of Molecular Medicine
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Adam, Vojtěch
- Babula, Petr
- Gumulec, Jaromír
- Hlavna, M.
- Holubová, M.
- Kizek, René
- Křížková, Soňa
- Masařík, Michal
- Sztalmachová, Markéta
- Balvan, J.
- Raudenská, M.
- Tanhauserova, V.
|
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |